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ABSTRACT
Objectives: To investigate the link between smoking exposure, telomere length 
and mortality, with emphasis on second-hand smoke (SHS) exposure and the duration 
of smoking cessation.
Results: A total of 1,018 participants died during follow-up (mean: 10.3 years). 
A 50 base-pair decrease in LTL was shown among cotinine-confirmed current versus 
never smokers. The 90th quantile of LTL decreased with increasing cotinine among 
never smokers, indicating a role of SHS. Longer telomeres with smoking cessation 
were indicated but limited to a 3-16 year period of abstaining smoking. When 
assessing mortality, we observed a lower risk of all-cause death for the second 
quintile compared to the first among never smokers (HR: 0.67, 95% CI: 0.52-0.87), 
and a higher risk was found among current smokers (HR: 1.89, 1.19-2.92).
Materials and Methods: We studied 6,456 nationally representative U.S. 
respondents with mortality follow-up through to 31 December 2011. Smoking 
status was assessed by interviews and cotinine levels. Relative leukocyte telomere 
length (LTL) was quantified by polymerase chain reaction (PCR). Multivariable linear 
regression was performed to examine LTL by smoking exposure, adjusted for age, 
sex, race/ethnicity, socioeconomic status, education, body mass index, alcohol 
consumption, and physical activity. We further estimated the association of LTL with 
cotinine levels using quantile regression, and with smoking cessation dynamics. Cox 
regression was used to estimate mortality by smoking status and LTL.
Conclusion: Our findings indicated a complex association between smoking, 
telomere length, and mortality. LTL alterations with SHS and smoking cessation 
warrant further investigation for translation to public health measures.
INTRODUCTION
Tobacco use is one of the leading global risk factors 
for mortality, particularly from chronic diseases including 
heart disease, diabetes and cancer [1, 2]. Cigarette smoking 
alone is considered responsible for up to 71% of lung 
cancer deaths worldwide [3]. With the causal relationship 
between smoking and lung cancer well established, [4] 
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recent studies have further focused on mitigating the risk 
for never smokers as well as former smokers. To this 
end, understanding the extent of how second-hand smoke 
(SHS) exposure and smoking cessation affect smoking-
related health outcomes is important to inform public 
policies.
Because a wide variety of diseases associated with 
smoking may be classified as age-related, ageing has 
emerged as in important comparative measure of health 
outcomes with regards to smoking and SHS exposure. 
Telomeres are nucleoprotein complexes that localize at the 
ends of eukaryotic chromosomes and perform functions 
for chromosomal protection, integration and replication 
[5]. Due to the end-replication problem, each somatic 
mitotic division results in the loss of telomeric repeats 
by 30 to 200 base pairs, leading to gradual telomere 
shortening [6]. Thus, telomere length can be used as a 
standard biomarker for cellular aging. Chronic exposure 
to biological insults such as oxidative stress may result in 
significantly shortened telomeres which in turn leads to 
cellular senescence and apoptosis [7, 8].
As a source of free radicals that may elicit 
oxidative stress and inflammation, [9] smoking has 
been hypothesized to promote telomere shortening, 
accelerating the ageing process and increasing the 
chances of developing age-related diseases [10, 11]. An 
inverse correlation between active smoking and telomere 
length has been indicated in some studies, [12–17] but 
little is known about their joint impact on mortality. 
Moreover, associations between SHS or smoking 
cessation and telomere length in the general population 
are rarely discussed. Therefore, to gain further insight 
into the association between smoking and longevity, 
we aimed to characterise associations between smoking 
exposures in relation to telomere length and mortality in a 
representative sample of the U.S. population.
RESULTS
Characteristics of study participants and 
corresponding mean telomere length are shown in 
Table 1. Mean age of study participants was 45.9 years. 
A total of 1,018 (16%) persons died during follow-up 
(mean: 10.3 years). Nearly half of the population (49%) 
were never smokers. Around 15% of never smokers 
reported SHS exposure either at home or at workplace. 
Mean LTL decreased with age (Supplementary Table 
S1, Supplementary Data), and was found to be longer 
among SHS-exposed as compared to SHS-unexposed 
never smokers (Supplementary Figure S1, Supplemental 
Information).
When comparing telomere length across self-
reported smoking status, we observed that being a current 
smoker was associated with a 50 bp decrease in LTL as 
compared to never smokers, with a 95% CI of –105 to 5 
bp in the age- and race/ethnicity-adjusted model. Similarly 
weak associations were observed when comparing current 
to former smokers (–37, 95% CI: –87 to 12) or former 
to never smokers (–12, 95% CI: –51 to 27). Further 
adjustments did not alter these results (Supplementary 
Table S2, Supplementary Data). Although similar results 
were found in analysis using cotinine-confirmed smoking 
status, a 50 bp decrease (95% CI: –85 to –1) in LTL was 
shown among cotinine-confirmed current as compared to 
never smokers.
Among self-reported current smokers, increasing 
pack-year of cigarettes corresponded to shorter telomere 
length, with a 169 bp decrease in LTL (95% CI: –257 to 
–81) for 30 pack-year of cigarettes and over (Ptrend=0.002). 
Among former smokers, a 100 bp higher mean telomere 
length was observed in those who had ceased smoking 
for 10–20 years as compared to those who had ceased 
smoking for fewer than five years. Neither SHS exposure 
at home or at work or serum cotinine showed any 
associations with LTL (Table 2). Similar associations 
were seen when using cotinine-confirmed smoking status, 
and when excluding participants with cancer diagnosis or 
history of COPD (results not shown).
We performed quantile regression analysis to further 
investigate the association between cotinine levels and 
LTL by self-reported smoking status. Overall, an inverse 
trend was observed between log-transformed cotinine and 
LTL among higher quantiles of telomere length across 
all groups, which suggested non-linear associations. In 
particular, shorter LTL in the 90th quantile was shown 
with increasing log-transformed cotinine levels among 
never smokers, with a 33 bp decrease (95% CI: –61 to –4). 
Similarly, an inverse association was shown between log 
cotinine and LTL in the 80th and 90th quantiles (Figure 1). 
No associations were observed among former smokers. 
When we further adjusted the models with pack-year of 
cigarette for current smokers, the observed association 
among current smokers was no present (results not 
shown).
We assessed the interplay between smoking status 
and LTL in relation to all-cause mortality. As shown in 
Kaplan-Meier curves (Figure 2), lower overall survival 
was observed with shorter telomere length for all smoking 
categories, particularly among never smokers (Plog-rank 
<0.05). In multivariable Cox regression, no associations 
were found LTL and risk of early death overall was 
found. In stratification analyses, weak inverse trends 
between LTL quintiles and risk of early death were 
observed among self-reported former and never smokers 
(Figure 3). A statistically significant lower risk of death 
was observedfor the 2nd, 3rd and 4th quintiles of LTL 
among never smokers (e.g. HR: 0.64, 95% CI: 0.43–0.96 
for the 4th quintile compared to the 1st). In contrast, a 
higher risk was observed among current smokers in the 
2nd quintile of LTL (HR: 1.87, 1.19–2.92). Results were 
similar with cotinine-confirmed smoking status (results 
not shown).
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Table 1: Weighted characteristics of study participants and mean telomere length
N Weighted % Mean LTL in kbp (SE)
Age, years
 20–30 1028 17.64 6.17 (0.04)
 30–40 1112 21.23 5.97 (0.04)
 40–50 1215 22.82 5.87 (0.04)
 50–65 1472 21.89 5.65 (0.04)
 ≥65 1629 16.40 5.42 (0.04)
Sex
 Male 3333 49.99 5.83 (0.04)
 Female 3123 51.01 5.81 (0.03)
Race/ethnicity
 Non Hispanic white 3337 74.46 5.79 (0.04)
 Non Hispanic black 1108 9.06 5.96 (0.05)
 Mexican American 1540 6.83 5.82 (0.05)
 Other 471 9.65 5.91 (0.07)
PIR
 <1 1115 13.82 5.90 (0.06)
 1–2 1656 20.50 5.77 (0.05)
 2–3 1051 15.63 5.80 (0.04)
 ≥3 2634 50.06 5.83 (0.04)
Education
 Less than high school 2129 20.73 5.71 (0.04)
 High school 1510 25.87 5.81 (0.04)
 Higher education 2817 53.40 5.87 (0.03)
Cancer diagnosis
 No 5911 92.04 5.84 (0.03)
 Yes 545 7.96 5.61 (0.04)
History of COPD
 No 5992 92.12 5.84 (0.03)
 Yes 464 7.88 5.63 (0.04)
Vigorously active
 No 5383 80.13 5.79 (0.03)
 Yes 1073 19.87 5.96 (0.04)
Body mass index (BMI), kg/m2
 <18.5 92 1.69 5.88 (0.06)
 18.5–25 1954 32.94 5.91 (0.04)
 25–30 2357 35.16 5.80 (0.04)
 ≥30 2053 30.21 5.76 (0.03)
(Continued )
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N Weighted % Mean LTL in kbp (SE)
Alcohol consumption
 Never 479 6.89 5.91 (0.07)
 Up to once a week 4715 70.65 5.80 (0.04)
 2–3 times per week 640 11.93 5.91 (0.04)
 4 times per week or more 622 10.53 5.78 (0.04)
Self-reported moking status
 Current smokers 1452 24.71 5.85 (0.03)
 Former smokers 1751 25.35 5.71 (0.03)
 Never smokers 3253 49.94 5.86 (0.04)
Serum cotinine (ng/mL)1
 <0.5 2633 40.00 5.79 (0.03)
 0.5–10 2010 31.12 5.86 (0.04)
 ≥10 1641 28.82 5.84 (0.04)
1Measured in 6,284 participants.
2Second-hand smoke (SHS) exposure at home, defined as presence of one or more smokers at home for never and current 
smokers. For current smokers, exposure was defined as presence of two or more smokers at home.
3Second-hand smoke (SHS) exposure at work, defined as being able to smell others’ smoking at workplace.
Table 2: Characteristics of smoking exposures and mean LTL by smoking status. 
Weighted % Mean LTL difference (bp) 95% CI
Current smokers
Years since started smoking
 <5 6.38 Reference Reference
 5–10 12.55 –23 –233, 185
 10–20 23.93 –47 –256, 161
 ≥20 57.14 48 –176, 273
 Ptrend 0.61
No. of cigarettes smoked per day
 <2 2.69 Reference Reference
 2–10 15.55 166 –93, 426
 10–20 28.08 103 –126, 332
 ≥20 53.68 41 –176, 259
 Ptrend 0.07
Pack-year of cigarette
 <15 46.75 Reference Reference
 15–30 25.48 –76 –168, 14
 ≥30 27.77 –169 –257, –81
 Ptrend 0.002
Log serum cotinine –20 –46, 5
(Continued )
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Weighted % Mean LTL difference (bp) 95% CI
Former smokers
Years since quitted smoking
 <5 13.97 Reference Reference
 5–10 14.44 51 –60, 163
 10–20 33.95 100 2, 197
 ≥20 37.64 113 –1, 227
 Ptrend 0.05
Years smoking when quitting
 <5 14.10 Reference Reference
 5–10 14.69 77 –80, 234
 10–20 26.88 25 –103, 153
 ≥20 44.33 1 –107, 109
 Ptrend 0.43
No. of cigarettes smoked per day 
when quitting
 <2 8.23 Reference Reference
 2–10 22.86 –94 –220, 32
 10–20 19.58 –105 –235, 25
 ≥20 49.32 –99 –239, 41
 Ptrend 0.61
Pack-year of cigarette
 <15 53.65 Reference Reference
 15-30 19.19 –63 –146, 19
 ≥30 27.16 –44 –148, 58
 Ptrend 0.34
Log serum cotinine –7 –20, 6
Never smokers
SHS exposure at home1 6.49 16 –109, 101
SHS exposure at work1 9.86 –8 –111, 95
Log serum cotinine –8 –20, 4
All models were adjusted by age, sex, race/ethnicity, PIR, education, BMI, vigorous physical activity, and alcohol intake.
1Second-hand smoke (SHS) exposure at home, defined as presence of one or more smokers at home for never smokers. 
Referents were those with negative responses to this definition.
2Second-hand smoke (SHS) exposure at work, defined as being able to smell others’ smoking at workplace. Referents were 
those with negative responses to this definition.
To further investigate the role of smoking cessation 
duration, we compared LTL for each t indicating time lag 
since abstaining or quitting smoking, between recoded 
smokers, i.e. current smokers and former smokers 
quitting <t years, and non-smokers which comprised 
never smokers and former smokers quitting ≥t years. 
As shown in Figure 4, we observed shorter LTL among 
recoded smokers compared to non-smokers with 3 to 
16 years of time since smoking cessation. No difference 
between the two recoded groups was observed beyond this 
time interval. For all-cause mortality, a similar analysis 
showed consistently higher risk of death among recoded 
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smokers as compared to non-smokers without any marked 
difference between time intervals since abstaining from 
smoking (results not shown).
DISCUSSION
Our findings strengthen evidence for an association 
between shorter telomere length with increasing smoking 
intensity. Increased cotinine levels corresponded to shorter 
telomeres among never smokers in higher quantiles of 
LTL, indicating non-linear associations and the role of 
SHS exposure. Among former smokers, a borderline 
inverse association was seen between telomere length 
and time after quitting smoking. The association between 
smoking cessation and LTL was further suggested to be 
strongest within 3 to 16 years of abstaining smoking. 
When assessing mortality, we found effect modification by 
smoking status in association between LTL and all-cause 
death.
To date, evidence regarding the association 
between SHS exposure or smoking cessation and 
telomere length remains scarce. In our study, mean 
LTL was longer with exposure to SHS compared to a 
lack of it, although no marked difference was found for 
either home or workplace SHS exposure. However, we 
observed shorter telomeres following increased cotinine 
levels among higher quantiles of LTL, indicating non-
linear associations. Non-linear patterns have been 
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Figure 1: Associations between log-transformed cotinine levels and quantiles of mean LTL, stratified by self-reported 
smoking status. All models were adjusted by age, sex, race/ethnicity, PIR, education, BMI, vigorous physical activity, and alcohol intake. 
The x-axes represent mean LTL value, and y-axes represent mean LTL difference for every log unit increase in cotinine levels. Black 
points indicate estimates for each decile, represented by adjacent numbers. Error bars represent 95% confidence intervals from bootstrap 
resampling.
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observed between other biological measures and health 
outcomes, for instance the J-shape curve observed 
between alcohol intake [18] or vitamin D [19] and 
mortality. As with these two lifestyle-related exposures, 
understanding of such associations is necessary for 
targeted interventions.
We found no difference in LTL between self-reported 
current, former and never smokers. This inconsistency 
has been previously reported (Supplementary Table 
S3), and several possible explanations are as follows. 
First, smoking status is mostly assessed by self-reported 
history which is prone to recall bias among other biases 
[20]. We addressed this by using cotinine-confirmed 
categories and observed slightly stronger associations 
overall between smoking exposures and LTL. Secondly, 
non-linear associations between smoking exposures 
and LTL may occur as previously mentioned. Finally, 
although telomere shortening is regarded as an indicator 
of ageing, the clinical and public health relevance of 
LTL as a biomarker of longevity is not fully understood 
[21]. In the NHANES population, this was shown by a 
lack of clear trends between LTL and mortality overall. 
Furthermore, our study showed effect modification of 
this association by smoking status, implying differential 
biological or socioeconomic pathways involved, which 
require mechanistic investigation.
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Figure 2: Kaplan-Meier curves for overall survival by quintiles of mean LTL (T/S ratio), stratified by self-reported 
smoking status at baseline.
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Figure 3: Hazard ratios (HRs) and 95% confidence intervals for all-cause mortality by quintiles of mean LTL (T/S 
ratio), stratified by self-reported smoking status at baseline.
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Figure 4: The dynamic of smoking cessation and telomere length. For any given t representing time since quitting smoking, 
mean LTL was compared between smokers, comprising current smokers and former smokers who quitted smoking up to t years ago, and 
non-smokers, which included never smokers and former smokers who quitted smoking more than t years ago. Points and lines indicate 
estimates of mean LTL difference in base pair between smokers and non-smokers for each t and their 95% confidence intervals, respectively. 
Bold points and shaded areas represent statistically significant differences.
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The present study implies that smoking cessation 
may be associated with less telomere attrition. A similarly 
positive association between duration of smoking 
cessation and telomere length has been reported in a 
study among older adults (50–75 years) in Germany [22]. 
Correspondingly, favourable age-related biological and 
health outcomes have been reported to follow smoking 
cessation, including decreased levels of inflammatory 
biomarkers [23], and reversal of lung and heart function, 
[24, 25] which may be accounted for by epigenetic 
changes [26]. Telomere elongation may also indicate 
reactivation of telomerase pathways as reported in some 
malignancies [27]. However, changes associated with 
malignant processes tend to be organ- or tissue-specific 
rather than systemic, and we found similar results after 
excluding cancer diagnosis. Alternatively, our results 
may represent certain smoking behaviours. For instance, 
relapse rate is highest (~60%) in the first three years of 
smoking cessation, [28] which may explain a lack of 
meaningful results for short-term cessation. Despite 
adjustment for age and lifestyle, a lack of association 
with longer periods of smoking cessation may have been 
unclear due to cumulative DNA-damaging effects from 
other exposures with later age [27]. Confirmation of any 
causal effect of smoking cessation on telomere length thus 
requires longitudinal data collection, which was beyond 
the scope of this study.
The strength of this study lies on the nationally 
representative sample included in the NHANES surveys. 
Our analysis included both self-reported history and 
objective assessment of nicotine exposure by measuring 
serum cotinine levels. One of the limitations of this study 
is that information was based on cross-sectional surveys. 
Whilst we were able to evaluate duration of smoking 
cessation, our findings only implied association rather 
than causation. Misclassification may have occurred since 
information on causes of death was collected by means of 
probabilistic matching [29]. However, such bias would be 
non-differential. The low number of cases also hampered 
analyses on specific causes of death. Although NHANES 
was designed to represent the general population of the 
US, those with higher exposure of active or second-hand 
smoking have increased mortality risk and are therefore 
more likely to die before being included in the surveys 
compared to less exposed or unexposed individuals. 
This may have led to an underestimation of associations 
observed in this study. Spurious correlations may also 
be of concern due to the small number of events which 
hampered statistical power in our subgroup analyses of 
mortality, prompting the need to confirm these findings in 
studies with longer follow-up period. Another limitation 
is that telomere length may be altered in carcinogenesis 
[30]. Although findings were similar when analyses were 
restricted to those without history of cancer or COPD, 
residual confounding may have occurred due to lack of 
information on cancer incidence and definitive diagnoses 
of COPD.
In summary, our findings corroborate associations 
between smoking exposures, biological ageing and 
mortality, and indicate the impact of second-hand smoke 
exposure and smoking cessation on ageing. Further 
investigations on biological and socioeconomic pathways 
underlying these findings may identify targets for 
intervention, and inform future clinical and public health 
policies aimed to reduce the burden caused by the smoking.
MATERIALS AND METHODS
Study population
The National Health and Nutrition Examination 
Survey (NHANES) is a cross-sectional health survey 
conducted by the National Center for Health Statistics 
(NCHS) in representative samples of the non-
institutionalized U.S. population [31]. Participants 
were selected through multistage stratified, clustered 
probability sampling. The survey included an interview 
conducted at home and an extensive physical examination, 
which included a blood sample taken in a mobile 
examination centre (MEC). This study was based on the 
continuous NHANES 1999–2002, which included 21,004 
participants, among whom 10,291 were 20 years old and 
above. From this population, we selected 10,262 adults 
who had complete data on self-reported smoking status. 
We subsequently excluded pregnant women (N=603) 
and those without available data on LTL measurements 
(N=2,313) or other covariates: poverty-to-income ratio, 
education level, body mass index (BMI), vigorous physical 
activity, and alcohol intake (N=890). Characteristics 
of study participants (age, sex, race/ethnicity) did not 
differ when missing values were excluded. We assumed 
missing values to have occurred completely at random and 
complete cases (N=6,456) were used in the analysis.
Telomere length assay
The telomere length assay was performed in the 
laboratory of Dr. Elizabeth Blackburn at the University 
of California, San Francisco, using the quantitative 
polymerase chain reaction (qPCR) method to measure 
telomere length relative to standard reference DNA (T/S 
ratio), as described in detail elsewhere [16, 32]. Each 
sample was assayed three times on three different days. 
The samples were assayed on duplicate wells, resulting 
in six data points. Sample plates were assayed in groups 
of three plates, and no two plates were grouped together 
more than once. Each assay plate contained 96 control 
wells with eight control DNA samples. Assay runs with 
eight or more invalid control wells were excluded from 
further analysis (<1% of runs). Control DNA values were 
used to normalize between-run variability to control for 
potential batch effects. Runs with more than four control 
DNA values falling outside 2.5 standard deviations from 
the mean for all assay runs were excluded from further 
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analysis (<6% of runs). For each sample, any potential 
outliers were identified and excluded from the calculations 
(<2% of samples). The mean and standard deviation of the 
T/S ratio were then calculated normally. The interassay 
coefficient of variation was 6.5%. T/S ratio was converted 
into base pairs (bp) using the following formula: (3,274 
+ 2,413 * (T/S)) [33]. The conversion from T/S ratio 
to bp was calculated based on comparison of telomeric 
restriction fragment (TRF) length from Southern blot 
analysis and T/S ratios using DNA samples from the 
human diploid fibroblast cell line IMR90 at different 
population doublings.
Mortality follow-up
Information on dates of death was obtained from 
data linkage of the NHANES dataset with the National 
Death Index (NDI). This linkage was performed by the 
NCHS through probabilistic matching with social security 
number, birth date, occupation, and other personal data, 
and confirmation with death certificate when possible 
[29]. Follow-up time was calculated from interview date/
examination date until date of death or end of study (31 
December 2011), whichever came first.
Assessment of smoking exposures
Participants were asked whether they had smoked 
at least 100 cigarettes in their entire life, and those who 
responded positively were asked whether they now smoke 
cigarettes every day, some days, or not at all. We defined 
current smokers as those who had smoked at least 100 
cigarettes during their lifetime and, at the time of the 
interview, reported smoking either every day or some days. 
Former smokers were those who reported smoking at least 
100 cigarettes during their lifetime but currently did not 
smoke. Never smokers were those who had not smoked 
100 cigarettes during their lifetime. We also identified 
SHS exposure at home and at workplace, defined as 
never smokers who answered ‘yes’ to the question “Does 
anyone who lives here smoke” or admitted that they could 
smell other people’s smoking at workplace, respectively. 
In addition to self-reported history, we additionally used 
measurement of serum cotinine, a major metabolite of 
nicotine [34] to construct a secondary smoking status. 
Serum cotinine (ng/mL) was measured by an isotope 
dilution-high performance liquid chromatography/
atmospheric pressure chemical ionization tandem mass 
spectrometry [35]. For the cotinine-confirmed smoking 
status, those with serum cotinine 10 ng/mL or above 
were considered current smokers regardless self-reported 
history, and never smokers with cotinine levels of 0.05 ng/
mL were regarded as being exposed to SHS [34, 36]. We 
further characterised former smokers based on the length of 
time since they quit smoking, years since started smoking 
and total cigarette smoked in a day. Former smokers were 
grouped by years since they quitted smoking and total 
cigarette smoked in a day when quitting. For both current 
and former smokers, pack-year of cigarette was calculated 
by dividing total cigarette smoked per day by total cigarette 
per pack, i.e. 20, and multiplying the result by the duration 
of smoking in years. We did not assess the use other types 
of tobacco such as cigars and snuff given the small number 
of participants using these products.
Other covariates
Race/ethnicity was categorised into Non-Hispanic 
white, Non-Hispanic black, Mexican-American, and 
others. We classified educational attainment as less than 
high school, high school equivalent, and higher than high 
school. SES was estimated with poverty-to-income ratio 
(PIR), a ratio of total family income to the official poverty 
threshold at the family level. A PIR <1 indicated that 
income was less than the level of poverty. We categorised 
PIR into <1, 1–2, 2–3, and ≥3, indicating lowest to highest 
SES [37]. A self-reported history of cancer diagnosis was 
based on a positive response to the question “Have you 
ever been told by a doctor or other health care professional 
that you had cancer or a malignancy of any kind”. 
Similarly, chronic obstructive pulmonary disease (COPD) 
was defined as self-reported history of chronic bronchitis 
or emphysema. Weight was measured with an electronic 
weight scale in pounds and automatically converted to 
kilograms. Participants only wore underwear, disposable 
paper gowns and foam rubber slippers. Standing height 
was measured with a fixed stadiometer to the nearest 1 
mm. Body mass index (BMI) was calculated from weight 
and height and classified into less than 18.5, 18.5–25, 
25–30, and 30 kg/m2 or greater [38]. Vigorous physical 
activity was described as reporting three or more physical 
activities of at least six metabolic equivalents (METs) per 
week, each with a duration of at least 10 minutes [39]. 
Frequency of alcohol consumption was collected during 
interview and categorised into never (had fewer than 12 
alcohol drinks throughout their life), up to once a week, 
2–3 times a week, and 4 times a week or more.
Statistical analysis
We estimated proportions of participant 
characteristics and corresponding mean LTL with the 
NHANES 2001–2002 sampling weights for genetic 
data subsample. Mean LTL (T/S ratio) in base pair 
was assessed as the outcome. First, we determined the 
associations between self reported smoking status and 
LTL using an age-, sex- and race/ethnicity-adjusted linear 
regression model. In the second model, we additionally 
adjusted for categories of PIR and education level given 
the impact of socioeconomic status on population health 
[40, 41]. Adjustments for BMI, vigorous physical activity 
and alcohol consumption were further performed in the 
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fully adjusted model, which was used for all subsequent 
analyses. A similar analysis was performed for cotinine-
confirmed smoking status.
We assessed the quantity and intensity of smoking, 
expressed as pack-year of cigarettes, and smoking duration 
for both current and former smokers, and duration since 
quitting smoking for former smokers only. SHS exposure 
at home and workplace was assessed for never smokers, 
and log-transformed levels of serum cotinine were in each 
group. Since altered telomere length has been observed 
with some malignancies and COPD, [30, 42] and given 
common pathways linked to smoking and these diseases 
such as inflammation, [43–46] a sensitivity analysis was 
performed by excluding participants reporting any history 
of cancer diagnosis or COPD. The NHANES data was 
prepared with Statistical Analysis Software (SAS) release 
9.4 (SAS Institute, Cary, NC) and survey-weighted analyses 
were performed with the survey package of R version 3.1.2 
(R Foundation for Statistical Computing, Vienna, Austria).
To further characterise the relationship between 
smoking, SHS exposure and telomere length, we 
performed quantile regression assessing difference in 
deciles of LTL with increasing log-transformed cotinine. 
This analysis predicted changes in a given quantile, e.g. 
median (0.5) of outcome variables instead of their mean, 
allowing identification of non-linear associations. [47] All 
models were adjusted for age, sex, race/ethnicity, PIR, 
education, BMI, vigorous physical activity and alcohol 
consumption. Analyses were stratified by smoking status 
(current, former and never smokers). For current smokers, 
we performed a sensitivity analysis by controlling for 
pack-year of smoking since smoking intensity may affect 
both cotinine levels [35] and telomere length. [16] The 
R quantreg package incorporating NHANES sampling 
weight replicates were used to obtain quantile regression 
estimates. Ninety-five percent confidence intervals were 
obtained using 100 bootstrap re-samples.
To gain further insight into associations between 
smoking exposures, telomere length and mortality, we 
displayed survival probability by LTL quintiles and 
smoking status using Kaplan-Meier curves. We further 
estimated hazard ratios (HRs) and 95% confidence 
intervals (CIs) of all-cause mortality by continuous values 
and quintiles of LTL for self-reported current, former, and 
never smokers. All models were adjusted for age, sex, 
race/ethnicity, PIR, education, BMI, vigorous physical 
activity and alcohol consumption. Analyses were repeated 
with cotinine-confirmed smoking status, and additional 
adjustment for pack-year of smoking was performed for 
current smokers. Due to the insufficient number of cases, 
we were unable to perform analyses by specific causes of 
death or characteristics of smoking exposures.
Finally, we sought to gain insight into the effect of 
smoking cessation dynamics on telomere length and risk 
of mortality, using duration since abstaining or quitting 
smoking as a proxy and a recoded binary variable for 
smoking status (smokers and non smokers). This approach 
has been previously used to investigate patterns of DNA 
methylation following smoking cessation. [26] For each 
value of t, reflecting the time since smoking cessation, 
those assigned as ‘smokers’ included current smokers 
and former smokers who quitted smoking <t years ago, 
and ‘non-smokers’ comprised never smokers and former 
smokers who quitted ≥t years ago. We employed survey-
weighted multivariable linear regression to compare LTL 
in base pairs between recoded smokers and non-smokers 
for each t. Therefore, for t=0, we assessed LTL among all 
current smokers with former and never smokers combined 
as the referent group, and for the highest t, we compared 
LTL among ever smokers against never smokers. 
Similarly, risk of dying from all causes was compared 
between the two recoded groups for each t. All models 
were adjusted for age, sex, race/ethnicity, PIR, education, 
BMI, vigorous physical activity and alcohol consumption.
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